What is Genomind?
Genomind operates as a specialized pharmacogenetic testing laboratory, bridging the gap between complex genetic data and actionable clinical outcomes. Founded by Dr. Ronald I. Dozoretz and Dr. Jay Lombard, the organization focuses on the underlying biological mechanisms of neuropsychiatric disorders. By providing clinicians with sophisticated diagnostic tools, Genomind enables a personalized medicine approach that optimizes treatment efficacy for patients suffering from mental health conditions. The company's market position is defined by its commitment to rigorous research and its ability to translate high-level neurological science into practical, patient-centric diagnostic solutions that improve long-term health outcomes.
How much funding has Genomind raised?
Genomind has raised a total of $92.2M across 8 funding rounds:
Series A
$20.9M
Other Financing Round
$5M
Private Equity
$6M
Other Financing Round
$17.9M
Series B
$31.9M
Multiple Rounds
$10.4M
Series A (2014): $21M with participation from Claritas Capital
Other Financing Round (2014): $5M led by Claritas Capital
Private Equity (2015): $6M supported by Claritas Capital
Other Financing Round (2016): $18M featuring Claritas Capital
Series B (2017): $31.9M backed by Silicon Valley Bank
Debt (2020): $1M with participation from PPP
Series C (2020): $4.5M, investors not publicly disclosed
Series D (2020): $4.9M supported by Claritas Capital
Key Investors in Genomind
Claritas Capital
Claritas Capital is an alternative investments firm based in Nashville, TN, specializing in venture capital and real estate. The firm has invested over $1 billion in innovative founders, entrepreneurs, and developers, focusing on healthcare, technology, and media/entertainment sectors.
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, funds management, and business valuation services.
Undisclosed Investors
What's next for Genomind?
With the support of its recent strategic investment, Genomind is well-positioned to scale its diagnostic infrastructure and expand its footprint in the personalized medicine market. The company's roadmap likely involves deepening its research into the genetic markers of neuropsychiatric health, thereby enhancing the predictive power of its testing platforms. As the healthcare industry shifts toward data-driven, individualized care, Genomind's focus on clinical utility and scientific innovation will be critical in maintaining its competitive advantage. Future growth will likely center on broader clinical adoption and the integration of its proprietary data into standard psychiatric care protocols, ensuring that the firm remains at the forefront of the intersection between genetics and mental health.
See full Genomind company page
